Author:
de Luis D. A.,Becerra A.,Lahera M.,Botella J. I.,Valero M. A.,Varela C.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference23 articles.
1. Molitch M.E., Elton R.L., Blackwell R.E. Bromocriptine as primary therapy for prolactinemicsecreting macroadenomas: results of a prospective multicentric study. J. Clin. Endocrinol. Metab. 1985, 60: 698–705.
2. Colao A., Merola B., Sarnacchiaro F. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinoma. Horm. Res. 1995, 44: 222–228.
3. Crosignani P.G., Ferrari C. Dopaminergic treatments for hyperprolactinemia. Baillieres Clin. Obstet. Gynaecol. 1990, 4: 441–445.
4. Razzaq R., O Halloran D.J., Beardwell C.G., Shalet S.M. The effects of CV 205-502 in patients with hyperprolactinemia intolerant and/or resistant to bromocriptine. Horm. Res. 1993, 39: 218–222.
5. Brue T., Pellegrini I., Gunz G. Effects of dopamine agonists CV 205-502 in human prolactinomas resistant to bromocriptine. J. Clin. Endocrinol. Metab. 1992, 74: 577–584.
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献